Reuters logo
BRIEF-Iovance Biotherapeutics announces FDA fast track designation for LN-144 for treatment of advanced melanoma
August 31, 2017 / 8:54 PM / a month ago

BRIEF-Iovance Biotherapeutics announces FDA fast track designation for LN-144 for treatment of advanced melanoma

Aug 31 (Reuters) - Iovance Biotherapeutics Inc

* Iovance Biotherapeutics announces FDA fast track designation for LN-144 for treatment of advanced melanoma Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below